Review



mass 1039 array platform  (Sequenom)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Sequenom mass 1039 array platform
    Mass 1039 Array Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mass+1039+array+platform/array+mass+sequenom+system/10__1016_slash_j__gendis__2025__101998-552-108-107
    Average 86 stars, based on 1 article reviews
    mass 1039 array platform - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Methylation:

    Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
    Article Snippet: .. 1030 1031 Figure 9 Methylation potentially contributes to the down-regulation of SNCA levels 1032 in breast cancer (BC). (A) Box-whisker plots display the promoter methylation levels 1033 of SNCA in BC tumor tissues compared with normal tissues, with analysis using a t-1034 test in TCGA via UALCAN. (B) Promoter methylation levels of SNCA in BC 1035 stratified by lymph node status (N0-N3) compared with normal tissues. (C) The CpG 1036 Finder tool predicted a potential CpG island within the SNCA promoter, identifying 1037 twenty-one CpG units. (D) The distribution of methylation degree of CpG sites in BC 1038 tissues and paired para-carcinoma tissues was analyzed using the Sequenom Mass 1039 Array platform. (E) The cluster diagram illustrates the differentially methylated 1040 regions between BC tissues and paired para-carcinoma tissues. (F) Quantitative PCR 1041 J urn al Pr e-p roo f 51 analysis was performed to assess SNCA expression in BC cell lines treated with 5-1042 Aza-CdR at a final concentration of 5 μM for 72 h. (G) The representative image 1043 demonstrates tumor growth in nude mice subcutaneously inoculated with MDA-MB-1044 453 cells, followed by treatment with 5-Aza-CdR. (H) Tumor weight was measured in 1045 the subcutaneous mouse models after sacrifice. (I) The expression levels of SNCA 1046 and TP53AIP1 in the mouse models were assessed by Western blotting (n = 3). ..

    Real-time Polymerase Chain Reaction:

    Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
    Article Snippet: .. 1030 1031 Figure 9 Methylation potentially contributes to the down-regulation of SNCA levels 1032 in breast cancer (BC). (A) Box-whisker plots display the promoter methylation levels 1033 of SNCA in BC tumor tissues compared with normal tissues, with analysis using a t-1034 test in TCGA via UALCAN. (B) Promoter methylation levels of SNCA in BC 1035 stratified by lymph node status (N0-N3) compared with normal tissues. (C) The CpG 1036 Finder tool predicted a potential CpG island within the SNCA promoter, identifying 1037 twenty-one CpG units. (D) The distribution of methylation degree of CpG sites in BC 1038 tissues and paired para-carcinoma tissues was analyzed using the Sequenom Mass 1039 Array platform. (E) The cluster diagram illustrates the differentially methylated 1040 regions between BC tissues and paired para-carcinoma tissues. (F) Quantitative PCR 1041 J urn al Pr e-p roo f 51 analysis was performed to assess SNCA expression in BC cell lines treated with 5-1042 Aza-CdR at a final concentration of 5 μM for 72 h. (G) The representative image 1043 demonstrates tumor growth in nude mice subcutaneously inoculated with MDA-MB-1044 453 cells, followed by treatment with 5-Aza-CdR. (H) Tumor weight was measured in 1045 the subcutaneous mouse models after sacrifice. (I) The expression levels of SNCA 1046 and TP53AIP1 in the mouse models were assessed by Western blotting (n = 3). ..

    Expressing:

    Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
    Article Snippet: .. 1030 1031 Figure 9 Methylation potentially contributes to the down-regulation of SNCA levels 1032 in breast cancer (BC). (A) Box-whisker plots display the promoter methylation levels 1033 of SNCA in BC tumor tissues compared with normal tissues, with analysis using a t-1034 test in TCGA via UALCAN. (B) Promoter methylation levels of SNCA in BC 1035 stratified by lymph node status (N0-N3) compared with normal tissues. (C) The CpG 1036 Finder tool predicted a potential CpG island within the SNCA promoter, identifying 1037 twenty-one CpG units. (D) The distribution of methylation degree of CpG sites in BC 1038 tissues and paired para-carcinoma tissues was analyzed using the Sequenom Mass 1039 Array platform. (E) The cluster diagram illustrates the differentially methylated 1040 regions between BC tissues and paired para-carcinoma tissues. (F) Quantitative PCR 1041 J urn al Pr e-p roo f 51 analysis was performed to assess SNCA expression in BC cell lines treated with 5-1042 Aza-CdR at a final concentration of 5 μM for 72 h. (G) The representative image 1043 demonstrates tumor growth in nude mice subcutaneously inoculated with MDA-MB-1044 453 cells, followed by treatment with 5-Aza-CdR. (H) Tumor weight was measured in 1045 the subcutaneous mouse models after sacrifice. (I) The expression levels of SNCA 1046 and TP53AIP1 in the mouse models were assessed by Western blotting (n = 3). ..

    Concentration Assay:

    Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
    Article Snippet: .. 1030 1031 Figure 9 Methylation potentially contributes to the down-regulation of SNCA levels 1032 in breast cancer (BC). (A) Box-whisker plots display the promoter methylation levels 1033 of SNCA in BC tumor tissues compared with normal tissues, with analysis using a t-1034 test in TCGA via UALCAN. (B) Promoter methylation levels of SNCA in BC 1035 stratified by lymph node status (N0-N3) compared with normal tissues. (C) The CpG 1036 Finder tool predicted a potential CpG island within the SNCA promoter, identifying 1037 twenty-one CpG units. (D) The distribution of methylation degree of CpG sites in BC 1038 tissues and paired para-carcinoma tissues was analyzed using the Sequenom Mass 1039 Array platform. (E) The cluster diagram illustrates the differentially methylated 1040 regions between BC tissues and paired para-carcinoma tissues. (F) Quantitative PCR 1041 J urn al Pr e-p roo f 51 analysis was performed to assess SNCA expression in BC cell lines treated with 5-1042 Aza-CdR at a final concentration of 5 μM for 72 h. (G) The representative image 1043 demonstrates tumor growth in nude mice subcutaneously inoculated with MDA-MB-1044 453 cells, followed by treatment with 5-Aza-CdR. (H) Tumor weight was measured in 1045 the subcutaneous mouse models after sacrifice. (I) The expression levels of SNCA 1046 and TP53AIP1 in the mouse models were assessed by Western blotting (n = 3). ..

    Multiple Displacement Amplification:

    Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
    Article Snippet: .. 1030 1031 Figure 9 Methylation potentially contributes to the down-regulation of SNCA levels 1032 in breast cancer (BC). (A) Box-whisker plots display the promoter methylation levels 1033 of SNCA in BC tumor tissues compared with normal tissues, with analysis using a t-1034 test in TCGA via UALCAN. (B) Promoter methylation levels of SNCA in BC 1035 stratified by lymph node status (N0-N3) compared with normal tissues. (C) The CpG 1036 Finder tool predicted a potential CpG island within the SNCA promoter, identifying 1037 twenty-one CpG units. (D) The distribution of methylation degree of CpG sites in BC 1038 tissues and paired para-carcinoma tissues was analyzed using the Sequenom Mass 1039 Array platform. (E) The cluster diagram illustrates the differentially methylated 1040 regions between BC tissues and paired para-carcinoma tissues. (F) Quantitative PCR 1041 J urn al Pr e-p roo f 51 analysis was performed to assess SNCA expression in BC cell lines treated with 5-1042 Aza-CdR at a final concentration of 5 μM for 72 h. (G) The representative image 1043 demonstrates tumor growth in nude mice subcutaneously inoculated with MDA-MB-1044 453 cells, followed by treatment with 5-Aza-CdR. (H) Tumor weight was measured in 1045 the subcutaneous mouse models after sacrifice. (I) The expression levels of SNCA 1046 and TP53AIP1 in the mouse models were assessed by Western blotting (n = 3). ..

    Western Blot:

    Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
    Article Snippet: .. 1030 1031 Figure 9 Methylation potentially contributes to the down-regulation of SNCA levels 1032 in breast cancer (BC). (A) Box-whisker plots display the promoter methylation levels 1033 of SNCA in BC tumor tissues compared with normal tissues, with analysis using a t-1034 test in TCGA via UALCAN. (B) Promoter methylation levels of SNCA in BC 1035 stratified by lymph node status (N0-N3) compared with normal tissues. (C) The CpG 1036 Finder tool predicted a potential CpG island within the SNCA promoter, identifying 1037 twenty-one CpG units. (D) The distribution of methylation degree of CpG sites in BC 1038 tissues and paired para-carcinoma tissues was analyzed using the Sequenom Mass 1039 Array platform. (E) The cluster diagram illustrates the differentially methylated 1040 regions between BC tissues and paired para-carcinoma tissues. (F) Quantitative PCR 1041 J urn al Pr e-p roo f 51 analysis was performed to assess SNCA expression in BC cell lines treated with 5-1042 Aza-CdR at a final concentration of 5 μM for 72 h. (G) The representative image 1043 demonstrates tumor growth in nude mice subcutaneously inoculated with MDA-MB-1044 453 cells, followed by treatment with 5-Aza-CdR. (H) Tumor weight was measured in 1045 the subcutaneous mouse models after sacrifice. (I) The expression levels of SNCA 1046 and TP53AIP1 in the mouse models were assessed by Western blotting (n = 3). ..



    Similar Products

    mass 1039 array platform  (Sequenom)
    86
    Sequenom mass 1039 array platform
    Mass 1039 Array Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mass+1039+array+platform/array+mass+sequenom+system/10__1016_slash_j__gendis__2025__101998-552-108-107
    Average 86 stars, based on 1 article reviews
    mass 1039 array platform - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results